Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients with Directly Acting Antiviral Agents.

Background: With the development of all oral, interferon-free directly acting antiviral (DAA) medications, treatment of Hepatitis C infection (HCV) in renal transplant recipients is possible, but limited data exists on its safety and efficacy. Methods: We performed a retrospective cohort analysis of patients transplanted at our center with HCV who have been started on DAAs. Primary endpoints included sustained virologic response (SVR) as defined as negative viral load at 12 weeks post completion of therapy and allograft function. Results: A total of 31 patients met inclusion criteria. The most commonly used regimen was sofosbuvir and ledipasvir (n=21). Of the treated patients, 100% had undetectable viral load at the completion of therapy. Of the 31 patients treated, 30 (97%) achieved SVR. Both graft and patient survival at most recent follow up was 100%. There was no significant change in glomerular filtration rate (GFR) before or after therapy (64.2+/-16.5 ml/min/BSA before vs. 58.9+/-17.5 ml/min/BSA after therapy, p=0.22), however, 3 patients now have GFR

http://ift.tt/2i1dIRM